The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Legal claims defining the scope of protection, as filed with the USPTO.
1. A peptide of from 9 to 25 amino acids in length, comprising the amino acid sequence of SSSGLHPPK (SEQ ID NO: 77), wherein said peptide is in the form of a pharmaceutically acceptable salt, wherein said peptide is modified and/or includes non-peptide bonds.
2. A fusion protein, comprising the amino acid sequence of SSSGLHPPK (SEQ ID NO: 77); and N-terminal amino acids 1-80 of HLA-DR antigen-associated invariant chain (Ii).
3. A pharmaceutical composition comprising (i) the peptide according to claim 1 , and (ii) a pharmaceutically acceptable carrier.
4. The peptide of claim 1 consisting of the amino acid sequence of SSSGLHPPK (SEQ ID NO: 77).
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
June 18, 2015
June 19, 2018
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.